Cancer Hematopoiesis and Immunology (CHI)

$80,150P30FY2025CANIH

University Of Michigan At Ann Arbor, Ann Arbor MI

Investigators

Linked publications, trials & patents

Paper 39713566 Paper 39693340 Paper 39585895 Paper 39574876 Paper 39574605 Paper 39565098 Paper 39563831 Paper 39515327 Paper 39509603 Paper 39499573 Paper 39487735 Paper 39485242 Paper 39483899 Paper 39480488 Paper 39470729 Paper 39462976 Paper 39438135 Paper 39419964 Paper 39386734 Paper 39351871 Paper 39349971 Paper 39323220 Paper 39311858 Paper 39276348 Paper 39251788 Paper 39208685 Paper 39182611 Paper 39154783 Paper 39126652 Paper 39117603 Paper 39103355 Paper 39073801 Paper 39059369 Paper 39044017 Paper 39036962 Paper 39024552 Paper 39020220 Paper 39018356 Paper 39008790 Paper 39005728 Paper 38992135 Paper 38979312 Paper 38977883 Paper 38973591 Paper 38968937 Paper 38958646 Paper 38937199 Paper 38919034 Paper 38915566 Paper 38915368 Paper 38914800 Paper 38899679 Paper 38888796 Paper 38888340 Paper 38883705 Paper 38871762 Paper 38821085 Paper 38818307 Trial NCT06732388 Trial NCT06195306 Trial NCT05941520 Trial NCT05630794 Trial NCT05411094 Trial NCT04939051 Trial NCT03148275 Trial NCT02007200 Trial NCT01789255 Trial NCT01195415 Trial NCT00967824 Trial NCT00955188 Trial NCT00900094 Trial NCT00433576 Trial NCT00330161 Trial NCT00098969 Trial NCT00064272 Trial NCT00027495 Trial NCT00005598 Trial NCT00003598 Trial NCT00003076 Patent 9745635 Patent 9606124 Patent 9284609 Patent 8969527 Patent 8940301 Patent 8580509 Patent 8211645 Patent 8202692 Patent 7718369 Patent 7598052 Patent 7253185 Patent 6916802 Patent 6890949 Patent 6569889 Patent 6255336 Patent 6051598 Patent 6040332 Patent 6030995 Patent 5952370 Patent 5945442 Patent 5916911

Abstract

The mission of University of Michigan Rogel Cancer Center Cancer Hematopoiesis and Immunology (CHI) Program is to generate new insights into the nature and biology of immunity and hematopoiesis during homoeostasis and in the settings of cancer and hematopoietic cell transplantation (HCT). The CHI programâs overarching goals are to delineate molecular mechanisms regulating immune/hematopoietic cells, their interactions with the microenvironment, and the development of therapeutic strategies that can be translated in an inter-programmatic manner. To build on advances from the last period, Program aims include: 1) Elucidate the mechanisms regulating immune and non-immune hematopoietic cell function during homeostasis, cancer progression, and cellular therapy; 2) Understand the mechanisms of cross-talk between immune cells and nonimmune cells in cancer therapy and HCT; and 3) Define key concepts, approaches, and reagents in preclinical studies to translate selected advances into the clinic to improve cancer outcomes and quality of life for patients and survivors. The CHI program is aligned with two Rogel strategic research priorities: i) Cancer initiation, progression, and resistance; and ii) Cancer treatment and care delivery paradigms. Program goals include exploration of molecular mechanisms regulating immune/hematopoietic cells and their interactions with the microenvironment, and the development of new treatment strategies via intra- and inter-programmatic translational collaborations. CHI member research interests are relevant to six of the nine Rogel cross-cutting research themes: Tumor Microenvironment and Metabolism; Molecular Determinants; Inflammation, Microbes and Immunity; Biomarkers; Health Access; and Targets and Therapeutics.

View original record on NIH RePORTER →